Salarius Pharmaceuticals, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | (Audited) | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $4,809,680 | $2,434,528 |
| Prepaid expenses and other current assets | 1,255,258 | 553,034 |
| Total current assets | 6,064,938 | 2,987,562 |
| Other assets | 32,094 | 35,412 |
| Total assets | $6,097,032 | $3,022,974 |
| Liabilities and stockholders' equity | ||
| Current liabilities: | ||
| Accounts payable | $1,104,184 | $936,994 |
| Accrued expenses and other current liabilities | 744,783 | 352,419 |
| Notes payable | — | 221,866 |
| Total liabilities | 1,848,967 | 1,511,279 |
| Commitments and contingencies (Note 4) | ||
| Stockholders' equity: | ||
| Common stock, $0.0001 par value; 100,000,000 shares authorized; 944,491 and 96,077 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively (1) | 94 | 10 |
| Additional paid-in capital (1) | 89,712,414 | 83,435,303 |
| Accumulated deficit | (85,464,443) | (81,923,618) |
| Total stockholders' equity | 4,248,065 | 1,511,695 |
| Total liabilities and stock holders' equity | $6,097,032 | $3,022,974 |
(1)Historical common stock and additional paid-in capital amounts have been recast to reflect the 1-for-8 and 1-for-15 reverse stock split effected in June 14, 2024 and August 15, 2025, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.